| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.7M | +17.0% | +198.6% |
| SG&A Expense | $5 | -100.0% | -100.0% |
| Operating Income | -$15 | +100.0% | +100.0% |
| Net Income | -$20.9M | -239.0% | -818.7% |
| EPS (Basic) | -$1.12 | -160.5% | -366.7% |
| EPS (Diluted) | -$1.12 | -160.5% | -366.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.7M | -10.4% | — |
| Current Assets | $9.8M | -11.1% | — |
| Total Assets | $10.0M | -16.4% | — |
| Current Liabilities | $10.7M | +24.7% | — |
| Total Liabilities | $10.8M | +24.1% | — |
| Stockholders' Equity | -$910K |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.2M | — | — |
| Investing Cash Flow | -$4.6M | — | — |
| Financing Cash Flow | $25.3M | — | — |
| -128.0% |
| -119.0% |